Stephanie Okey - Mar 28, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Mar 28, 2024
Transactions value $
-$491,575
Form type
4
Date filed
4/2/2024, 04:35 PM
Previous filing
Feb 16, 2024
Next filing
Jun 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $320K +17.5K +291.67% $18.29* 23.5K Mar 28, 2024 Direct
transaction CRNX Common Stock Sale -$812K -17.5K -74.47% $46.38 6K Mar 28, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (right to buy) Options Exercise $0 +17.5K $0.00* 0 Mar 28, 2024 Common Stock 17.5K $18.29 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $46.38 per share. The range of sales prices on the transaction date was $46.06 to $46.66 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F2 The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.